The purpose of this study is to determine if once-daily treatment with colchicine, compared to placebo, is effective in preventing gout flares in patients who are initiating therapy with allopurinol.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
82
daily 0.6 mg colchicine dosing for 16 weeks
daily placebo dosing for 16 weeks
background therapy
Number of Gout Flares Per Participant From Day 1 to Week 16
Time frame: Day 1 to Week 16
Percentage of Participants With at Least 1 Gout Flare From Day 1 to Week 16
Time frame: Day 1 to Week 16
Percentage of Participants With at Least 2 Gout Flares From Day 1 to Week 16
Time frame: Day 1 to Week 16
Mean Number of Gout Flare Days Per Participant Assessed From Day 1 to Week 16
Time frame: Day 1 to Week 16
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Alabaster, Alabama, United States
Unnamed facility
Mesa, Arizona, United States
Unnamed facility
Upland, California, United States
Unnamed facility
Trumbull, Connecticut, United States
Unnamed facility
DeBary, Florida, United States
Unnamed facility
Jacksonville, Florida, United States
Unnamed facility
Kissimmee, Florida, United States
Unnamed facility
Canton, Georgia, United States
Unnamed facility
Boise, Idaho, United States
Unnamed facility
Lexington, Kentucky, United States
...and 27 more locations